<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Tanisha Choudhury on Medium]]></title>
        <description><![CDATA[Stories by Tanisha Choudhury on Medium]]></description>
        <link>https://medium.com/@tanishachoudhury121?source=rss-a971934735fa------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*4TcL6lVbO_7ukqMIvJNuiA.jpeg</url>
            <title>Stories by Tanisha Choudhury on Medium</title>
            <link>https://medium.com/@tanishachoudhury121?source=rss-a971934735fa------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Wed, 18 Nov 2026 20:23:04 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@tanishachoudhury121/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[The Frontier of Oncology: Exploring CRISPR-Based Interventions]]></title>
            <link>https://medium.com/@tanishachoudhury121/the-frontier-of-oncology-exploring-crispr-based-interventions-ae542cff4c67?source=rss-a971934735fa------2</link>
            <guid isPermaLink="false">https://medium.com/p/ae542cff4c67</guid>
            <category><![CDATA[gene-editing]]></category>
            <category><![CDATA[crispr]]></category>
            <category><![CDATA[cancer-treatments]]></category>
            <category><![CDATA[cancer]]></category>
            <dc:creator><![CDATA[Tanisha Choudhury]]></dc:creator>
            <pubDate>Sun, 12 Oct 2025 13:58:02 GMT</pubDate>
            <atom:updated>2025-10-12T13:58:02.897Z</atom:updated>
            <content:encoded><![CDATA[<p>For decades, cancer has challenged medicine as one of the most complex and devastating diseases. Traditional treatments like chemotherapy, radiation, and surgery have saved millions of lives, but they often come with significant side effects, and can never guarantee long-term remission.</p><p>Despite decades of research and new drug discoveries, cancer remains one of the world’s leading causes of death, responsible for nearly one in every six deaths <strong>globally</strong>. What makes it so difficult to treat is its adaptability; cancer cells can evolve, resist therapy, and return even stronger after initial treatment.</p><p>The search for more precise and less harmful therapies has led scientists to a new frontier: <strong>gene editing.</strong></p><p>At the center of this frontier is <strong>CRISPR-Cas9</strong>, a revolutionary tool often described as “molecular scissors.” Instead of targeting the cancer after it develops, CRISPR allows researchers to go deeper — to the person’s DNA itself, where mutations first arise. By editing, or repairing faulty genes, CRISPR offers the potential, not just to treat cancer way more effectively, <strong>but possibly to prevent it altogether.</strong></p><p>Unlike chemotherapy or radiation, which destroy both healthy and cancerous cells, CRISPR has the ability to single out the exact mutations that drive tumor formation. This method, from treating symptoms to rewriting the biological code that causes them, represents one of the most extraordinary transformations in modern medicine.</p><p>This article will explore how CRISPR is<strong> reshaping oncology,</strong> the breakthroughs already made in research, and the challenges that remain before gene editing becomes a standard weapon in the fight against cancer.</p><p>We will dive deeper into how far the science has come, what ethical and safety issues still stand in the way, and why CRISPR may be the most promising — and controversial — leap forward in the history of cancer treatment.</p><p>Cancer is ultimately a disease of the genes. At it’s core, it arises when mutations occur in <strong>somatic cells</strong> — the cells that make up most of the body.</p><p>Normally, these cells follow a strict life cycle. They grow, divide when needed, and self-destruct of they are damaged or old. <strong>Mutations can disrupt this balance</strong>, causing cells to ignore growth signals, avoid programmed cell death, and start to multiply uncontrollably.</p><p>Every healthy cell in the human body is programmed with a set of instructions encoded in its DNA. These instructions basically control when the cell should divide, repair itself, or die. When mutations appear in these instructions, the system can malfunction. Over time, if enough of these errors accumulate in key genes, the cell can start too lose control of its normal cycle and begin dividing without limits. This uncontrolled growth is, ultimately, <strong>how cancer starts.</strong></p><figure><img alt="Figure 1: infographic showing the difference between cancer cells and normal cells in microscopic view" src="https://cdn-images-1.medium.com/max/1024/0*LDhLyeE9tDaf-u3T" /><figcaption>Figure 1: infographic showing the difference in the cancer cells multiplying in comparison too the normal cells multiplying in microscopic view</figcaption></figure><p>There are two major types of genes that are involved in cancer development:</p><ul><li>Oncogenes</li><li>Tumor Suppressor Genes</li></ul><p><strong>Oncogenes </strong>are the genes that normally help cells grow and divide. When they are mutated, they act like a “stuck accelerators,” pushing cells to divide continuously and start to form tumors. Examples include <strong>KRAS </strong>and <strong>MYC</strong>, which are often mutated in lung and breast cancers.</p><p><strong>Tumor Suppressor Genes </strong>are the genes that normally act as the brakes on cell division, repairing DNA damage or triggering cell death when necessary. When they are inactivated or lost, cells can grow unchecked. Well-known tumor suppressors include <strong>TP53</strong>, which is mutated in roughly half of all human cancers, and <strong>BRCA1/2,</strong> associated with breast and ovarian cancers.</p><p>Because these genetic changes drive the disease, cancer is essentially a problem of faulty DNA instructions. This makes it an ideal candidate for targeted gene-editing approaches like CRISPR, which can precisely modify or repair the mutations at the source.</p><p>This genetic foundation can also explain why each cancer case can be so unique — two patients with the same cancer type may have completely different sets of mutations. Understanding these differences at the microscopic level allows scientists to design personalized therapies that target each patient’s <strong>exact mutations</strong>, rather than just relying on one-size-fits-all treatments.</p><p>By understanding which genes are mutated and how they affect cell behavior, scientists can begin to develop therapies that attack cancer at its root rather than just treating it’s symptoms.</p><p>CRISPR-Cas9 is a revolutionary gene-editing tool that has transformed modern biology. At a basic level, CRISPR allows scientists to precisely target and modify specific genes, making it far more efficient and accurate than older gene-editing methods.</p><p>Before CRISPR, scientists relied on approaches like <strong>Zinc Finger Nucleases</strong> and <strong>TALENs</strong>, which used engineered proteins to cut DNA at specific sites. These methods were effective, but difficult to design, slow, and expensive, limiting their practical use. CRISPR can now simplify this process, requiring only a small RNA sequence to guide the “molecular scissors” to the right spot.</p><p>This simplicity is what makes CRISPR so revolutionary — instead of building complex proteins for each new gene target, scientists can simply “program” CRISPR by changing the RNA sequence. In a way, CRISPR turns gene editing into a form of biological coding.</p><p>CRISPR was originally discovered as part of a <strong>bacterial immune system.</strong> Bacteria use it to defend against viruses by cutting viral DNA and storing fragments as a memory of past infections. Scientists started to adapt this system for human cells, <strong>creating a programmable method to cut DNA at specific locations.</strong></p><p>This system works in two main parts:</p><ul><li>Guide RNA (gRNA)</li><li>Cas9 Enzyme</li></ul><p><strong>Guide RNA: </strong>This RNA molecule is designed to match a specific DNA sequence in the target gene. It acts like a GPS, directing the CRISPR machinery to the <strong>exact location</strong> that needs editing.</p><p><strong>Cas9 Enzyme: </strong>Cas9 are the “molecular scissors” that cut the DNA at the spot specified by the gRNA. Once the DNA is cut, the cell’s <strong>natural repair mechanisms</strong> kick in, allowing researches then to either disable a gene that causes the disease, correct a mutation or insert a new gene to enhance cell function.</p><p>When Cas9 makes its precise cut, the cell rushes to repair the break; which is where scientists can step in. They can trick the repair process into “fixing” the gene in a specific way, either by <strong>removing </strong>a harmful mutation or <strong>inserting </strong>healthy DNA. This approach gives researchers a level of control over genetic information.</p><p>What makes CRISPR particularly exciting in cancer research is it’s precision and adaptability. Scientists can design gRNA’s to target mutated oncogenes or tumor suppressor genes, potentially halting tumor growth at the genetic level. Because it works directly on DNA, CRISPR offers the possibility of treating the underlying cause of cancer, rather than just managing it’s symptoms.</p><p>For example, instead of bombarding the body with chemotherapy — which kills all rapidly dividing cells, healthy or not — CRISPR could quite literally silence the single mutation driving tumor formation. The dream is, to one day, program CRISPR like a medicine: identify the mutation, design the RNA, and edit the cancer out.</p><p>Since it’s discovery in 2012, CRISPR has quickly became one of the <strong>most promising tools in cancer research.</strong> Scientists are using it to study how cancer develops, identify which genes encourage tumor growth, and even start to design new types of therapies that attack cancer at the genetic level.</p><p>CRISPR has now allowed researchers to move <strong>beyond </strong>simply observing cancer cells to actively starting to manipulate them in precise ways. This ability to “rewrite” genetic instructions gives scientists unprecedented control over experimental cancer models and offers a glimpse into treatments that could one day be highly personalized.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/542/0*o2BCnigAVf3rNQYb.png" /><figcaption>Figure 2: infographic explaining CRISPR-Cas9</figcaption></figure><p>One of the most direct uses of CRISPR in oncology is targeting oncogenes. By “knocking out” these genes, researches can now<strong> stop tumor cells from dividing </strong>or make them more<strong> sensitive to existing treatments.</strong> For example, laboratory studies have successfully used CRISPR to <strong>disable </strong>the KRAS oncogene in lung and pancreatic cancer cells, reducing tumor formation in animal models.</p><p>These experiments are crucial because KRAS mutations are found in a significant portion of aggressive cancers and<strong> are difficult to target with traditional drugs.</strong> CRISPR provides a tool to study these mutations in controlled settings and test new therapeutic approaches.</p><p>CRISPR is also being used to repair tumor suppressor genes, like <strong>TP53 </strong>and <strong>BRCA1</strong>, which normally help control cell division and repair DNA damage. When these genes are mutated, cancer cells can grow unchecked. Early experiments have shown that restoring their normal function can slow down or reverse tumor growth in lab conditions.</p><p>Beyond individual genes, researchers are now starting to explore CRISPR for complex genetic networks that <strong>contribute </strong>to cancer progression. By editing multiple genes simultaneously, scientists can better understand how cancer cells survive and adapt — things that are pretty much impossible to achieve with older gene-editing technologies.</p><p>The most exciting process, though, has came from c<strong>ombining CRISPR with immunotherapy,</strong> especially CAR-T cell therapy. In this treatment, a patient’s immune cells are removed, genetically engineered to recognize and attack cancer cells, and then <strong>reintroduced into the body.</strong></p><p>These trials don’t just demonstrate safety, but also look at <strong>effectiveness</strong>, with early results<strong> showing improved immune response and potential tumor reduction in some patients.</strong> Researchers hope that this type of approach can eventually be applied to solid tumors and more diverse cancer types.</p><p>CRISPR makes this process even faster and more precise. In 2020, the first clinical trials using CRISPR-edited cells to treat patients with leukemia and lymphoma showed that the <strong>modified cells could safely target cancer cells without severe side effects </strong>— which is a major milestone for gene-edited cancer therapy.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*tc9ldxlPBoj3S8hX.png" /><figcaption>Figure 3: timeline showing the different experiments and research timeline.</figcaption></figure><p>Although these findings are still in somewhat early stages, they mark a major step towards personalized, gene-based medicine. Each patient’s cancer is driven by unique mutations, and CRISPR now offers the potential to design treatments tailored specifically to these genetic changes.</p><p>Even though CRISPR offers hope for treating cancer at it’s genetic roots, it also can raise major ethical and safety questions that scientists and policymakers are still trying to solve.</p><p>The biggest concern is precision, or rather, the lack of it. Even though CRISPR is often described as a <strong>“genetic scissor,”</strong> it could possibly cut the wrong section of DNA. Off-target mutations like this might just damage healthy genes, potentially leading to new health problems, or even starting to trigger cancer instead of curing it.</p><p>Even though laboratory studies show that off-target effects can sometimes be minimized, the unpredictability still becomes a major hurdle for clinical applications. Researchers have to <strong>carefully design guide RNAs</strong> and go through <strong>extensive </strong>testing to make sure that edits occur only at the intended site. Even a single change can have long-term consequences for a patient’s health.</p><p>Another challenge is long-term safety. Editing a gene doesn’t always mean the chance will start to behave predictably over time. Cells divide, mutate, and interact with the environment, and scientists still don’t fully understand how edited cells might behave years after treatment. This uncertainty makes scientists cautious about moving too quickly into human trials.</p><p>Furthermore, some edited cells might evolve differently than expected, potentially creating new risks or reducing the therapy’s effectiveness over time. Consistent studies are necessary to monitor patients for years, or even decades, to fully understand the outcomes of gene-edited therapies.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*cM4nGZ8zk5eLp7Nn" /><figcaption>Figure 4: infographic of all the effects that can be caused.</figcaption></figure><p>Beyond safety, CRISPR also brings up ethical debates about how far gene-editing should go. Using it to cure cancer is widely supported, but what about using the same technology to enhance traits like intelligence, or physical ability? This “slippery slope” between therapy and enhancement worries many bioethicists.</p><p>Bioethicists argue that while curing disease is widely acceptable, using CRISPR for non-medical enhancements could deepen social inequality and raise questions about consent, fairness, and the definition of “normal” human traits. Global consensus on these limits is still far from reality, making it a consistent topic in debates and policy discussions.</p><p>Finally, there’s the issue of access and fairness. Advanced genetic therapy could be extremely expensive at first, raising concerns that only wealthy patients could benefit. As gene-editing technologies evolve, ensuring equal access, and clear global regulations, will be essential to prevent widening healthcare inequalities.</p><p>Without careful planning, CRISPR could unintentionally widen the gap in healthcare availability, creating a world where life-saving genetic therapies are only available to only a small portion of the population. Policymakers, scientists, and global organizations are beginning to discuss ways that can ensure both safety and equity in gene-editing treatments.</p><p>CRISPR-Cas9 has transformed how scientists think about curing cancer — not by destroying cancer cells with radiation or chemicals, but by rewriting the very instructions that allow them to form. It’s a bold vision, that could one day, start to make treatments more precise, personal, and permanent. By, like every tool in science, CRISPR comes with it’s own challenges.</p><p>As researches continue to refine gene-editing techniques and make sure they’re safe, the line between hope and hype will depend on responsibility, and how we choose to use this power. If guided by careful science, transparent ethics, and equal access, CRISPR could finally mark the turning point where cancer stops being a sentence, and becomes a solvable puzzle written in our DNA.</p><h3>Author’s Note:</h3><p>Hi, I’m Tanisha Choudhury. I am a 14-year old student at The Knowledge Society (TKS) in Calgary, Canada. I have a passion for exploring the frontiers of science and technology, particularly in areas like AI, gene editing, and biomedical innovation.</p><p>Outside of school, I like to research how emerging technologies can improve our lives, solve complex problems, and push the boundaries of what we think is possible. Writing this article allowed me to combine my interest in biology with the exciting possibilities of CRISPR, and to share these discoveries in a way that is accessible and engaging.</p><p>You can find me on my <a href="https://www.linkedin.com/in/tanisha-choudhury-4a3a9037b/"><strong>LinkedIn</strong></a><strong>,</strong> where I try to reflect as much as I can about events, programs, and cool opportunities.</p><p>I hope that this article can inspire other young researchers to explore the vast universe of technology, ethics, and medicine, and to ask the big questions about how we can use these tools that we have at our expense for the greater good.</p><h3>Sources:</h3><ul><li><a href="https://med.umn.edu/news/new-gene-editing-therapy-shows-early-success-fighting-advanced-gi-cancers">https://med.umn.edu/news/new-gene-editing-therapy-shows-early-success-fighting-advanced-gi-cancers</a></li><li><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3298009/">https://pmc.ncbi.nlm.nih.gov/articles/PMC3298009/</a></li><li><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11490091/">https://pmc.ncbi.nlm.nih.gov/articles/PMC11490091/</a></li><li><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10310991/">https://pmc.ncbi.nlm.nih.gov/articles/PMC10310991/</a></li><li><a href="https://www.insideprecisionmedicine.com/topics/oncology/crispr-therapy-eliminates-50-of-head-and-neck-tumors-in-preclinical-study/">https://www.insideprecisionmedicine.com/topics/oncology/crispr-therapy-eliminates-50-of-head-and-neck-tumors-in-preclinical-study/</a></li><li><a href="https://www.worldwidecancerresearch.org/cancer-and-cancer-research-explained/cancer-myths-and-questions/why-is-cancer-so-hard-to-cure/">https://www.worldwidecancerresearch.org/cancer-and-cancer-research-explained/cancer-myths-and-questions/why-is-cancer-so-hard-to-cure/</a></li><li><a href="https://www.synthego.com/crispr-cancer">https://www.synthego.com/crispr-cancer</a></li><li><a href="https://innovativegenomics.org/news/crispr-clinical-trials-2024/">https://innovativegenomics.org/news/crispr-clinical-trials-2024/</a></li><li><a href="https://www.mskcc.org/news/truth-behind-three-natural-cures">https://www.mskcc.org/news/truth-behind-three-natural-cures</a></li><li><a href="https://my.clevelandclinic.org/health/treatments/cancer-treatment">https://my.clevelandclinic.org/health/treatments/cancer-treatment</a></li><li><a href="https://cancer.ca/en/treatments/treatment-types">https://cancer.ca/en/treatments/treatment-types</a></li><li><a href="https://hsph.harvard.edu/news/the-cancer-miracle-isnt-a-cure-its-prevention-2/">https://hsph.harvard.edu/news/the-cancer-miracle-isnt-a-cure-its-prevention-2/</a></li><li><a href="https://www.cancer.org/cancer/understanding-cancer/history-of-cancer/cancer-treatment-chemo.html">https://www.cancer.org/cancer/understanding-cancer/history-of-cancer/cancer-treatment-chemo.html</a></li></ul><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=ae542cff4c67" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>